NO20053430L - Sammensetninger og fremgangsmater for foroket mukosal levering av Y2 reseptor-bindende peptider og fremgangsmater for behandling og forebygging av fedme. - Google Patents
Sammensetninger og fremgangsmater for foroket mukosal levering av Y2 reseptor-bindende peptider og fremgangsmater for behandling og forebygging av fedme.Info
- Publication number
- NO20053430L NO20053430L NO20053430A NO20053430A NO20053430L NO 20053430 L NO20053430 L NO 20053430L NO 20053430 A NO20053430 A NO 20053430A NO 20053430 A NO20053430 A NO 20053430A NO 20053430 L NO20053430 L NO 20053430L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- peptide
- subject
- fluid
- compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 title 1
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 108010088847 Peptide YY Proteins 0.000 abstract 6
- 102100029909 Peptide YY Human genes 0.000 abstract 6
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 abstract 5
- 210000003169 central nervous system Anatomy 0.000 abstract 4
- 239000012530 fluid Substances 0.000 abstract 3
- 210000002381 plasma Anatomy 0.000 abstract 3
- 210000001519 tissue Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- -1 peptide YY compound Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2271—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/322,266 US7166575B2 (en) | 2002-12-17 | 2002-12-17 | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| US49322603P | 2003-08-07 | 2003-08-07 | |
| US50117003P | 2003-09-08 | 2003-09-08 | |
| US51078503P | 2003-10-10 | 2003-10-10 | |
| US51729003P | 2003-11-04 | 2003-11-04 | |
| US51881203P | 2003-11-10 | 2003-11-10 | |
| PCT/US2003/040538 WO2004056314A2 (en) | 2002-12-17 | 2003-12-17 | Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053430D0 NO20053430D0 (no) | 2005-07-14 |
| NO20053430L true NO20053430L (no) | 2005-09-15 |
Family
ID=32686401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053430A NO20053430L (no) | 2002-12-17 | 2005-07-14 | Sammensetninger og fremgangsmater for foroket mukosal levering av Y2 reseptor-bindende peptider og fremgangsmater for behandling og forebygging av fedme. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7186691B2 (https=) |
| EP (1) | EP1581245A2 (https=) |
| JP (1) | JP2006516262A (https=) |
| AU (1) | AU2003299722A1 (https=) |
| BR (1) | BR0316685A (https=) |
| CA (1) | CA2510199A1 (https=) |
| CO (1) | CO5700705A2 (https=) |
| EA (1) | EA008829B1 (https=) |
| EC (1) | ECSP055839A (https=) |
| MA (1) | MA27535A1 (https=) |
| MX (1) | MXPA05006572A (https=) |
| NO (1) | NO20053430L (https=) |
| WO (1) | WO2004056314A2 (https=) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| DK1808438T3 (da) | 1999-06-29 | 2014-10-27 | Mannkind Corp | Rensning og stabilisering af peptid og proteiner i lægemidler |
| WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
| WO2004066966A2 (en) * | 2003-01-17 | 2004-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Peptide yy analogs |
| EP1713514B1 (en) * | 2004-01-28 | 2021-11-24 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| WO2005078454A2 (en) * | 2004-02-09 | 2005-08-25 | Nastech Pharmaceutical Company Inc. | Methods for determining the amount of peptide yy in blood |
| US7279457B2 (en) | 2004-03-12 | 2007-10-09 | Biodel, Inc. | Rapid acting drug delivery compositions |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| EP2060266B1 (en) * | 2004-03-17 | 2011-08-10 | 7TM Pharma A/S | Y4 selective receptor agonist PP2-36 for therapeutic interventions |
| WO2006007412A2 (en) * | 2004-06-16 | 2006-01-19 | Nastech Pharmaceutical Company Inc. | Peptide yy formulations having increased stability and resistance to microbial agents |
| MX2007000510A (es) * | 2004-07-12 | 2007-03-29 | Emisphere Tech Inc | Composiciones para suministrar peptido yy y agonistas de pyy. |
| WO2006091231A2 (en) * | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| PL1786784T3 (pl) | 2004-08-20 | 2011-04-29 | Mannkind Corp | Kataliza syntezy diketopiperazyn |
| KR101644250B1 (ko) | 2004-08-23 | 2016-07-29 | 맨카인드 코포레이션 | 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염 |
| PA8660701A1 (es) * | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| AU2005327331A1 (en) * | 2005-02-08 | 2006-08-17 | Woodford Associates Limited | Alcoholic beverage enriched with 1H216O |
| WO2006085785A1 (en) * | 2005-02-08 | 2006-08-17 | Timantti Ab | Non-alcoholic beverage enriched with 1h216o |
| EA012881B1 (ru) * | 2005-03-05 | 2009-12-30 | Сергей Павлович Соловьёв | Косметическая композиция с повышенным содержаниемho |
| WO2006096084A1 (en) * | 2005-03-11 | 2006-09-14 | Vada Consulting Limited | Methods for intradermal, transdermal or transmucosal delivery of biologically active substances |
| CN101146543A (zh) * | 2005-03-11 | 2008-03-19 | 维达咨询有限公司 | 轻制药用水和治疗组合物及其制备方法 |
| CN101146448A (zh) * | 2005-03-11 | 2008-03-19 | 维达咨询有限公司 | 用于消毒无生命表面的组合物 |
| US20080160100A1 (en) * | 2005-03-11 | 2008-07-03 | Igor Anatolievich Pomytkin | Method For Stimulating Hair Growth And Regeneration |
| RU2275920C1 (ru) * | 2005-04-01 | 2006-05-10 | Игорь Анатольевич Помыткин | Способ лечения новообразований |
| WO2007008778A2 (en) * | 2005-07-11 | 2007-01-18 | Nastech Pharmaceutical Company Inc. | Formulations for enhanced mucosal delivery of pyy |
| CN104324362B (zh) | 2005-09-14 | 2018-04-24 | 曼金德公司 | 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法 |
| WO2007069934A1 (en) * | 2005-12-12 | 2007-06-21 | Vada Consulting Limited | Method of treating metabolic syndrome |
| US20080292718A1 (en) * | 2005-12-12 | 2008-11-27 | Igor Anatolievich Pomytkin | Method for Suppression Appetite and Food Intake |
| WO2007070563A2 (en) * | 2005-12-13 | 2007-06-21 | Harkness Pharmaceuticals, Inc. | Stable solid forms of enterostatin |
| US20070149442A1 (en) * | 2005-12-13 | 2007-06-28 | Byron Rubin | Non-hygroscopic compositions of enterostatin |
| EP1973558A4 (en) * | 2005-12-13 | 2009-12-23 | Harkness Pharmaceuticals Inc | METHODS OF TREATING OBESITY WITH ENTEROSTATIN |
| IN2015DN00888A (https=) | 2006-02-22 | 2015-07-10 | Mannkind Corp | |
| US8106013B2 (en) | 2006-05-19 | 2012-01-31 | Georgia Tech Research Corporation | ABC transporter ligand GATX1 |
| RU2301067C1 (ru) * | 2006-06-19 | 2007-06-20 | Сергей Павлович Соловьев | Средство и способ для повышения половой активности человека |
| US8084022B2 (en) * | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US7998927B2 (en) * | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US7425542B2 (en) * | 2006-06-23 | 2008-09-16 | Aegis Therapeutics, Inc. | Stabilizing alkylglycoside compositions and methods thereof |
| JP2009542813A (ja) * | 2006-07-11 | 2009-12-03 | ハルクネスス プハルマセウティカルス，インコーポレイテッド | 飽食因子を使用して肥満を治療する方法 |
| EP2049138A4 (en) | 2006-07-14 | 2011-11-09 | Georgia Tech Res Inst | CLC KANALLIGAND |
| CN101511868B (zh) | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | 毒蜥外泌肽融合蛋白 |
| EP2061433B1 (en) * | 2006-09-08 | 2011-02-16 | Johns Hopkins University | Compositions for enhancing transport through mucus |
| GB0708226D0 (en) * | 2007-04-27 | 2007-06-06 | 7Tm Pharma As | Y-receptor agonists |
| WO2009002867A2 (en) * | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
| US8889622B2 (en) * | 2007-07-25 | 2014-11-18 | Washington University | Methods of inhibiting seizure in a subject |
| AU2008303922A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of the peptide His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe alone or in combination with the peptide Gly-Ard-Gly-Asp-Asn-Pro-OH as a therapeutic agent |
| MX344166B (es) * | 2008-02-08 | 2016-12-07 | Ambrx Inc | Leptina-polipeptidos modificados y sus usos. |
| JP5497006B2 (ja) | 2008-04-14 | 2014-05-21 | ザ ジェネラル ホスピタル コーポレイション | 膵管腺癌の検出および治療のためのプレクチン−１標的化剤 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| ES2929343T3 (es) | 2008-06-13 | 2022-11-28 | Mannkind Corp | Inhalador de polvo seco accionado por aspiración para la administración de fármacos |
| KR101628410B1 (ko) | 2008-06-20 | 2016-06-08 | 맨카인드 코포레이션 | 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법 |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| WO2010068414A2 (en) * | 2008-11-25 | 2010-06-17 | Bowen Richard L | Methods for treating obesity related disease |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| DK2405963T3 (da) | 2009-03-11 | 2013-12-16 | Mannkind Corp | Apparat, system og fremgangsmåde til at måle modstand i en inhalator |
| CN104721825B (zh) | 2009-06-12 | 2019-04-12 | 曼金德公司 | 具有确定比表面积的二酮哌嗪颗粒 |
| US9260500B2 (en) | 2009-07-02 | 2016-02-16 | Takeda Pharmaceutical Company Limited | Peptide and use thereof |
| WO2011020114A2 (en) * | 2009-08-14 | 2011-02-17 | Allergan, Inc. | Methods of treating cancer using tachykinin retargeted endopeptidases |
| US8207651B2 (en) | 2009-09-16 | 2012-06-26 | Tyco Healthcare Group Lp | Low energy or minimum disturbance method for measuring frequency response functions of ultrasonic surgical devices in determining optimum operating point |
| KR101026864B1 (ko) | 2009-10-08 | 2011-04-12 | (주)송호바이오메드 | 고 수용성 ２―하이드록시프로필―베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물 |
| WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| JP5819949B2 (ja) | 2010-06-10 | 2015-11-24 | ミダテック リミテッド | ナノ粒子フィルム送達システム |
| IL223742A (en) | 2010-06-21 | 2016-06-30 | Mannkind Corp | A dry powder inhaler and preparation for it |
| WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| AU2012236150B2 (en) | 2011-04-01 | 2016-03-31 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
| RU2476227C2 (ru) * | 2011-04-14 | 2013-02-27 | Ольга Георгиевна Мельникова | Способ снижения избыточного веса |
| DE102011103347B4 (de) * | 2011-05-27 | 2014-10-30 | Meda Pharma Gmbh & Co. Kg | Nasale pharmazeutische Formulierung |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| BR112014009686A2 (pt) | 2011-10-24 | 2018-08-07 | Mannkind Corp | composição analgésica inalável, pó seco e método para tratar dor |
| WO2013090278A2 (en) * | 2011-12-11 | 2013-06-20 | Recro Pharma, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
| US8962577B2 (en) | 2012-03-16 | 2015-02-24 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| JP6138904B2 (ja) | 2012-03-16 | 2017-05-31 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート |
| ES3055223T3 (en) | 2012-05-03 | 2026-02-10 | Alcon Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| JP6360039B2 (ja) | 2012-05-03 | 2018-07-18 | カラ ファーマシューティカルズ インコーポレイテッド | 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法 |
| US9533068B2 (en) | 2012-05-04 | 2017-01-03 | The Johns Hopkins University | Drug loaded microfiber sutures for ophthalmic application |
| CN104619369B (zh) | 2012-07-12 | 2018-01-30 | 曼金德公司 | 干粉药物输送系统和方法 |
| US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
| CN104902922B (zh) | 2012-11-13 | 2017-12-12 | 阿道恰公司 | 包含经取代阴离子化合物的速效胰岛素制剂 |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| AU2014228415B2 (en) | 2013-03-15 | 2018-08-09 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| US10017554B2 (en) | 2013-04-10 | 2018-07-10 | University Of Copenhagen | Neuropeptide Y-derived peptides |
| MX375448B (es) | 2013-07-18 | 2025-03-06 | Mannkind Corp | Composiciones farmacéuticas en polvo seco estables al calor y métodos. |
| US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| KR20240126072A (ko) | 2015-01-27 | 2024-08-20 | 더 존스 홉킨스 유니버시티 | 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제 |
| US20170081366A1 (en) * | 2015-09-22 | 2017-03-23 | Kyungpook National University Industry - Academic Cooperation Foundation | Novel Peptides for Preventing or Treating Bone Diseases and Use Thereof |
| HK1257499A1 (zh) | 2015-11-12 | 2019-10-25 | Graybug Vision, Inc. | 用於治疗的聚集性微粒 |
| AU2018265415A1 (en) | 2017-05-10 | 2019-10-31 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
| WO2018213468A1 (en) * | 2017-05-16 | 2018-11-22 | The University Of Chicago | Compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism |
| WO2019147650A1 (en) * | 2018-01-23 | 2019-08-01 | Gila Therapeutics, Inc. | Peptide yy pharmaceutical formulations, compositions, and methods |
| US12496279B2 (en) | 2019-04-11 | 2025-12-16 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| CN117979954A (zh) * | 2021-09-22 | 2024-05-03 | 辉凌有限公司 | 促肾上腺皮质激素肽组合物及使用方法 |
| WO2026015643A1 (en) * | 2024-07-12 | 2026-01-15 | Pulmosim Therapeutics Llc | Dry powder inhalation compositions and methods for treating or preventing pulmonary arterial hypertension |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH657779A5 (de) | 1982-10-05 | 1986-09-30 | Sandoz Ag | Galenische zusammensetzungen enthaltend calcitonin. |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US6391343B1 (en) | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
| ATE147976T1 (de) | 1991-01-15 | 1997-02-15 | Hemosphere Inc | Protein nanomatrizen und verfahren zur herstellung |
| US5616311A (en) | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
| US5725804A (en) | 1991-01-15 | 1998-03-10 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
| SG45429A1 (en) | 1992-07-07 | 1998-01-16 | Continental Pet Technologies | Method for forming multi-layer preform and container with low crystallizing interior layer |
| DK0678018T3 (da) | 1993-01-06 | 2003-04-28 | Kinerton Ltd | Ion molekylærkonjugater af bionedbrydelige polyestere og bioaktive polypeptider |
| KR960701653A (ko) | 1993-03-29 | 1996-03-28 | 발라수브라마니암 엠비카이파칸 | 펩타이드 yy의 유사체 및 그의 용도 |
| RO117259B1 (ro) | 1993-08-09 | 2001-12-28 | Biomeasure Inc. | Derivaţi peptidici, terapeutici |
| US5696093A (en) | 1994-10-28 | 1997-12-09 | Crc For Biopharmaceutical Research Pty Limited | Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides |
| US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
| US5912227A (en) | 1995-01-27 | 1999-06-15 | North Carolina State University | Method of enhancing nutrient uptake |
| US6558708B1 (en) | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| US5716643A (en) | 1995-06-07 | 1998-02-10 | Hemosphere Inc. | Large scale production of medicine coated crosslinked protein microspheres |
| US6017897A (en) * | 1995-06-07 | 2000-01-25 | Pasteur Merieux Connaught Canada | Nucleic acid respiratory syncytial virus vaccines |
| FR2736265B1 (fr) * | 1995-07-07 | 1997-09-26 | Forgeot Marcel | Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6013633A (en) | 1997-08-07 | 2000-01-11 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| CA2271788A1 (en) | 1996-11-13 | 1998-05-22 | University Of Cincinnati | Analogs of peptide yy and uses thereof |
| GB9707934D0 (en) * | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
| US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| JP2002503254A (ja) | 1997-06-05 | 2002-01-29 | ヘモスフィア，インコーポレイテッド | フィブリノゲンをコーティングしたミクロスフィア |
| IS4518A (is) * | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
| IT1293088B1 (it) | 1997-07-10 | 1999-02-11 | Isi Ist Sierovaccinogeno Ital | Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in |
| US6737408B1 (en) | 1997-08-07 | 2004-05-18 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| AU9185598A (en) | 1997-09-25 | 1999-04-12 | Banyu Pharmaceutical Co., Ltd. | Novel neuropeptide y receptor antagonists |
| DE69907870T2 (de) | 1998-01-29 | 2004-03-04 | Kinerton Ltd., Blanchardstown | Verfahren zur herstellung von absorbierbaren mikropartikeln |
| US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
| US5968748A (en) | 1998-03-26 | 1999-10-19 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human HER-2 expression |
| US6017879A (en) | 1998-04-03 | 2000-01-25 | B.M.R.A. Corporation B.V. | Template associated NPY Y2-receptor agonists |
| US7745216B2 (en) * | 1999-02-10 | 2010-06-29 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
| US7396809B1 (en) | 1999-02-10 | 2008-07-08 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
| US6391855B1 (en) * | 1999-06-02 | 2002-05-21 | Adherex Technologies, Inc. | Compounds and methods for modulating junctional adhesion molecule-mediated functions |
| EP2123293A3 (en) | 2000-12-14 | 2010-09-08 | Amylin Pharmaceuticals, Inc. | Peptide YY and petide YY agonists for treatment of metabolic disorders |
| CN100350968C (zh) * | 2001-09-24 | 2007-11-28 | 皇家创新有限公司 | 饮食行为的改进 |
| KR20040058324A (ko) | 2001-11-26 | 2004-07-03 | 다이이찌 산토리 파마 가부시키가이샤 | 경비흡수용 의약 조성물 |
| EP1474163A2 (en) | 2002-01-10 | 2004-11-10 | Imperial College Innovations Limited | Modification of feeding behavior |
| WO2003105763A2 (en) | 2002-06-14 | 2003-12-24 | Amylin Pharmaceuticals, Inc. | Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof |
-
2003
- 2003-12-17 BR BR0316685A patent/BR0316685A/pt not_active IP Right Cessation
- 2003-12-17 CA CA 2510199 patent/CA2510199A1/en not_active Abandoned
- 2003-12-17 EP EP03800002A patent/EP1581245A2/en not_active Withdrawn
- 2003-12-17 MX MXPA05006572A patent/MXPA05006572A/es not_active Application Discontinuation
- 2003-12-17 JP JP2005502646A patent/JP2006516262A/ja not_active Withdrawn
- 2003-12-17 EA EA200501007A patent/EA008829B1/ru not_active IP Right Cessation
- 2003-12-17 WO PCT/US2003/040538 patent/WO2004056314A2/en not_active Ceased
- 2003-12-17 AU AU2003299722A patent/AU2003299722A1/en not_active Abandoned
- 2003-12-23 US US10/745,069 patent/US7186691B2/en not_active Expired - Fee Related
-
2004
- 2004-01-30 US US10/768,288 patent/US7157426B2/en not_active Expired - Fee Related
-
2005
- 2005-06-07 EC ECSP055839 patent/ECSP055839A/es unknown
- 2005-06-15 MA MA28337A patent/MA27535A1/fr unknown
- 2005-06-16 CO CO05058645A patent/CO5700705A2/es not_active Application Discontinuation
- 2005-07-14 NO NO20053430A patent/NO20053430L/no not_active Application Discontinuation
-
2006
- 2006-08-25 US US11/467,509 patent/US20070129299A1/en not_active Abandoned
- 2006-11-20 US US11/561,825 patent/US20070197437A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004056314A3 (en) | 2005-03-31 |
| EA008829B1 (ru) | 2007-08-31 |
| NO20053430D0 (no) | 2005-07-14 |
| US20070129299A1 (en) | 2007-06-07 |
| BR0316685A (pt) | 2005-11-01 |
| AU2003299722A1 (en) | 2004-07-14 |
| US20040157777A1 (en) | 2004-08-12 |
| US20070197437A1 (en) | 2007-08-23 |
| MA27535A1 (fr) | 2005-09-01 |
| MXPA05006572A (es) | 2005-12-14 |
| CO5700705A2 (es) | 2006-11-30 |
| US7157426B2 (en) | 2007-01-02 |
| EA200501007A1 (ru) | 2006-02-24 |
| WO2004056314A2 (en) | 2004-07-08 |
| EP1581245A2 (en) | 2005-10-05 |
| US20040209807A1 (en) | 2004-10-21 |
| WO2004056314B1 (en) | 2005-09-29 |
| CA2510199A1 (en) | 2004-07-08 |
| ECSP055839A (es) | 2006-03-01 |
| US7186691B2 (en) | 2007-03-06 |
| JP2006516262A (ja) | 2006-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053430L (no) | Sammensetninger og fremgangsmater for foroket mukosal levering av Y2 reseptor-bindende peptider og fremgangsmater for behandling og forebygging av fedme. | |
| US12612430B2 (en) | Peptides | |
| MXPA05013340A (es) | Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento. | |
| ATE223230T1 (de) | Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1 | |
| BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
| US12337065B2 (en) | Compositions for treating viral infections and methods for same | |
| WO2002043746A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
| EA200501710A1 (ru) | Замещённые карбоновые кислоты | |
| NO20015931L (no) | Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin | |
| US20240218016A1 (en) | Peptides and their use in the treatment of inflammation | |
| NO330954B1 (no) | Anvendelse av en forbindelse for fremstilling av et legemiddel for behandling av en pasient som lider av sarkoidose. | |
| KR20250143851A (ko) | 신규한 다기능성 올리고펩타이드 | |
| DE59308848D1 (de) | Anwendung von urodilatin bei lungen- und bronchialerkrankungen | |
| ES2842523T3 (es) | Métodos y composiciones para el tratamiento de la artritis | |
| BR0011880A (pt) | Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica | |
| Morrison et al. | Juvenile respiratory papillomatosis: acyclovir reassessed | |
| TNSN05162A1 (en) | Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity | |
| BR0316123A (pt) | Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico | |
| NO20016301L (no) | Terapeutiske midler | |
| RU2004128444A (ru) | Способы и композиции для лечения желудочно-кишечной токсичности, вызванной цитодеструктивной терапией |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |